Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

• Główni autorzy: Carlos Escobar (Autor), Cristóbal Morales (Autor), Margarita Capel (Autor), Susana Simón (Autor), Ferran Pérez-Alcántara (Autor), Elisenda Pomares (Autor)
• Format: Książka
• Wydane: BMC, 2022-02-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract Background The objective of this study was to carry out a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of the DECLARE-TIMI 58 trial. Methods A discrete event...